Acute miliary tuberculosis, unspecified
ICD-10 A19.2 is a billable code used to indicate a diagnosis of acute miliary tuberculosis, unspecified.
Acute miliary tuberculosis is a disseminated form of tuberculosis (TB) characterized by the presence of numerous small lesions (miliary nodules) throughout the lungs and other organs. This condition arises when Mycobacterium tuberculosis spreads through the bloodstream, leading to a systemic infection. Patients may present with nonspecific symptoms such as fever, night sweats, weight loss, and fatigue, alongside respiratory symptoms like cough and chest pain. Diagnosis typically involves a combination of clinical evaluation, imaging studies such as chest X-rays or CT scans, and microbiological tests including sputum smear and culture for Mycobacterium tuberculosis. The acute nature of this condition necessitates prompt treatment, often involving a multi-drug regimen to combat potential drug resistance. Monitoring for treatment efficacy and adverse effects is crucial, as is adherence to public health protocols, including contact tracing and isolation of infectious patients to prevent further transmission. The unspecified designation indicates that the specific site of miliary TB involvement is not detailed, which can complicate treatment planning and epidemiological tracking.
Detailed clinical notes on symptoms, diagnostic tests, and treatment plans.
Patients presenting with respiratory symptoms and systemic signs of infection.
Consideration of drug resistance patterns and public health reporting.
Pulmonary function tests, imaging results, and treatment response.
Patients with respiratory distress and abnormal chest imaging.
Monitoring for respiratory complications and adherence to TB treatment.
Used to confirm TB infection in patients with suspected miliary TB.
Document the reason for testing and results.
Infectious disease specialists may require additional follow-up testing.
Common symptoms include fever, night sweats, weight loss, fatigue, cough, and chest pain. Symptoms can be nonspecific, making diagnosis challenging.
Diagnosis typically involves clinical evaluation, imaging studies (like chest X-rays or CT scans), and microbiological tests such as sputum smear and culture.
Treatment usually involves a multi-drug regimen including isoniazid, rifampin, pyrazinamide, and ethambutol, with close monitoring for drug resistance.
Public health measures include contact tracing, isolation of infectious patients, and monitoring for outbreaks to prevent further transmission.
